Metagenomi Therapeutics (MGX) Stock
Small biotech developing gene editing tools from microbes. Here's the price, business snapshot, and what's worth knowing about Metagenomi Therapeutics in October 2026.
Metagenomi Technologies, LLC (ticker MGX) is a small-cap biotechnology company (market capitalisation US$118.23m) focused on discovering and developing gene‑editing systems derived from microbial genomes. The firm seeks novel CRISPR-like enzymes and related tools that could be applied to therapeutics, research reagents or industrial biotechnology, with potential to be progressed internally or licenced to partners. As an early-stage life sciences company, Metagenomi typically carries higher scientific, regulatory and commercial risk than larger pharma peers; progress is often milestone-driven and funding needs can lead to dilution. Investors commonly monitor preclinical data, partnership announcements, licensing deals and regulatory milestones as indicators of progress. This summary is for educational purposes only and not personalised investment advice — returns are not guaranteed and the share price may be volatile. Consider your risk tolerance and seek independent advice or perform further due diligence before investing.
Metagenomi Therapeutics (MGX) Stock Forecast
Analyst price target, next 12 months
$15.00
+1370.6% vs today's $1.02
Price range over the last 12 months
Close to its 12-month low
Analysts covering Metagenomi Therapeutics have a consensus 12-month target of $15.00, above the current price of $1.02.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Metagenomi's stock, predicting its value could rise significantly.
Financial Health
Metagenomi Therapeutics is generating steady revenue and cash flow, but its overall financial health is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Small-cap growth story
Early‑stage technology can offer upside if platforms validate, but small‑cap biotech stocks are typically volatile and fundraising may dilute shareholders.
Novel editing platforms
The company explores microbial‑derived gene‑editing systems that could be licenced or developed further, though scientific and regulatory hurdles remain.
Partnerships and deals
Collaborations or licensing agreements can de‑risk development and create revenue paths, yet progress depends on successful R&D and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
